{
}
The Swiss stock market faced a downturn, with the SMI index dropping below 12,500, primarily due to a significant decline in UBS shares amid capital concerns. While some companies like Lonza and Medacta saw gains, others, including Swatch and Sonova, struggled as uncertainty from international tariff disputes continued to weigh on investor sentiment.
The Swiss stock market closed lower, with the SMI down 0.40% amid global concerns over Donald Trump's new tariffs on key trading partners, which investors fear could harm the economy. While the services sector in Switzerland showed growth, manufacturing faced significant challenges, leading to workforce cuts. Notable stock movements included Julius Bär dropping 12.7% and Lonza rising 2.7%.
UBS has upgraded Novartis to a 'Buy' rating with a target price of 111 Swiss francs, following a review of the company's strong quarterly results. Analyst Matthew Weston has adjusted his estimates accordingly, reflecting confidence in Novartis' performance.
UBS has rated NOVARTIS AG as a 'Buy', but the information provided is for informational purposes only and does not constitute a recommendation to buy or sell. Investing in securities carries risks, including the potential total loss of capital, and expert investment advice is recommended. No liability for the accuracy or completeness of the information is assumed, and the content reflects the views of individual authors rather than wallstreetONLINE.
Novartis AG is a leading global pharmaceutical company, with sales primarily in oncology (29.9%), immunology (17.2%), and cardiovascular, renal, and metabolic diseases (14.1%). By the end of 2023, it will operate 33 production sites worldwide, with sales distributed across Europe (33%), the USA (39.5%), Asia-Africa-Australasia (20.5%), and Canada and Latin America (7%).
UBS has reiterated its Buy recommendation for Novartis, maintaining a target price of 111 E, indicating a potential upside of 16%. Following strong Q4 2024 results, sales and core EBIT forecasts for 2025-29 have been increased by approximately 3% annually. Novartis anticipates mid- to high-single-digit sales growth and high-single- to low-double-digit growth in core operating income for 2025.
UBS has reiterated its Buy recommendation for Novartis, maintaining a target price of €111, indicating a 16% upside potential. Following strong Q4 2024 results, UBS has increased sales and core EBIT projections for 2025-29 by approximately 3% annually, anticipating mid- to high-single-digit sales growth and high- to low-single-digit core EBIT growth for 2025.
UBS has reiterated its Buy recommendation for Novartis, maintaining a target price of €111, indicating a potential upside of 16%. Following strong Q4 2024 results, UBS has increased sales and core EBIT forecasts for 2025-29 by approximately 3% annually. Novartis anticipates mid- to high-single-digit sales growth and high-single- to low-double-digit growth in core operating income for 2025.
UBS has reiterated its recommendation on Novartis stock, as reported by Cercle Finance and published by BOURSORAMA. The analysis is provided for informational purposes only, with BOURSORAMA disclaiming any responsibility for its content and ensuring no conflicts of interest affect its objectivity.
UBS has maintained its 'Buy' rating for Novartis, setting a price target of 111 Swiss francs. Analyst Matthew Weston has adjusted his estimates following the company's strong quarterly results released on Monday.
Novartis AG
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
Swiss stock market declines as UBS and Sonova shares fall sharply
Swiss Franc
Sonova R
Logitech International S.A.
PolyPeptide Group AG
Novartis AG
Galderma Group N
ABB Ltd
Julius Bär Gruppe AG
Zurich, Agence générale Christian Meier SA
Lonza Group AG
Medacta Group SA
The Swatch Group AG
Nestlé S.A.
Hoffmann-La Roche AG
CHE
Francesco Siccardi
Show more
05:52 04.02.2025
global markets decline as trump tariffs raise economic concerns
Swiss Franc
Euro
United States Dollar
Chinese Yuan
Singapore Dollar
Logitech International S.A.
Novartis AG
ABB Ltd
Sika AG
RICHEMONT, Intellectual Property Services
Lonza Group AG
The Swatch Group AG
Nestlé S.A.
Hoffmann-La Roche AG
Sandoz Group AG
USA
CHN
CHE
CAN
Francisco Ballester
John Plassard
Peter Stenico
Show more
18:01 03.02.2025
ubs upgrades novartis to buy with target price of 111 francs
12:50 03.02.2025
ubs rates novartis ag as buy with investment risks highlighted
12:50 03.02.2025
novartis ag sales breakdown and global production footprint overview
12:43 03.02.2025
Novartis receives buy recommendation with growth expectations for 2025
12:23 03.02.2025
ubs maintains buy rating on novartis with target price of 111 euros
12:19 03.02.2025
ubs maintains buy rating on novartis with target price of 111 euros
12:16 03.02.2025
ubs maintains positive outlook on novartis stock analysis released
12:16 03.02.2025
ubs maintains buy rating for novartis with target of 111 francs
11:50 03.02.2025
Trending
Subcategory
Countries:
Companies:
Currencies:
People: